Analyst Ronald Kamdem of Morgan Stanley maintained a Buy rating on Healthpeak Properties (DOC – Research Report), with a price target of $25.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Ronald Kamdem has given his Buy rating due to a combination of factors related to Healthpeak Properties’ recent financial performance and strategic initiatives. The company’s fourth-quarter financial results exceeded expectations, with funds from operations adjusted (FFOa) surpassing consensus estimates. This positive performance was driven by strong cash adjusted net operating income (NOI) growth, which increased by 5.4% year-over-year.
Moreover, despite the slightly conservative guidance for 2025, which was marginally below consensus, the strategic expansion in key areas such as lab leasing and outpatient medical facilities shows promising growth potential. The company’s decision to increase its dividend by 1.7% and shift to monthly payments starting in April further enhances its attractiveness to investors. These factors collectively underpin Kamdem’s optimistic outlook for Healthpeak Properties, justifying a Buy rating.
In another report released yesterday, BMO Capital also maintained a Buy rating on the stock with a $25.50 price target.